Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophagus Disorder Clear all
Recruiting Phase 4 Interventional

The Mechanism Versus PPI Trial

NCT06999577
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Cough, Throat Clearing, Dysphonia, Reflux
Interventions
Omeprazole 40 MG, Laryngeal Recalibration Therapy, GERD Lifestyle Recommendations
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Deigo, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 31, 2026, 7:52 AM EDT
Not yet recruiting No phase listed Observational

Ursodeoxycholic Acid in Barrett's Endotherapy

NCT07756710
View directory record Official record
Conditions
Barrett's Esophagus With Dysplasia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Not listed Not applicable Interventional

Novel Endoluminal Clinical TreAtment of Reflux

NCT03090607
View directory record Official record
Conditions
GERD
Interventions
Aluvra™, Saline
Device · Drug
Lead sponsor
Impleo Medical Inc.
Industry
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 31, 2026, 7:52 AM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection

NCT02810652
View directory record Official record
Conditions
Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, Hepatobiliary Cancer, Colon Cancer
Interventions
Usual Care, Perioperative Geriatrics Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 31, 2026, 7:52 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

NCT04225026
View directory record Official record
Conditions
Esophagitis
Interventions
GC4419 (avasopasem manganese)
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Gilbert, Arizona • Tampa, Florida • Columbus, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

NCT00524121
View directory record Official record
Conditions
Esophageal Cancer
Interventions
erlotinib hydrochloride, immunohistochemistry staining method, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
65 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 31, 2026, 7:52 AM EDT
Terminated Phase 1 Interventional

A Study of SGN-STNV in Advanced Solid Tumors

NCT04665921
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 31, 2026, 7:52 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 31, 2026, 7:52 AM EDT
Terminated Phase 2 Interventional Results available

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

NCT04510285
View directory record Official record
Conditions
Esophagogastric Tumors, Gastric Cancer, Gastric Tumor, Esophageal Cancer, Esophageal Neoplasms, Esophageal Tumor, GastroEsophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Tumor, Gastroesophageal Junction Cancer
Interventions
Trastuzumab, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Edwards CLASP TR EFS

NCT03745313
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Edwards PASCAL Transcatheter Valve Repair System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117
View directory record Official record
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

NCT01522768
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Afatinib and Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 31, 2026, 7:52 AM EDT
Terminated Not applicable Interventional Results available

Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

NCT02114606
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Cytosponge™ Cell Collection Device
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 31, 2026, 7:52 AM EDT
Recruiting Phase 1 Interventional

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

NCT07227168
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
Interventions
STRO-004, Pembrolizumab
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Completed No phase listed Observational

"Evaluation of the PillCam™ESO Capsule in the Detection of Esophageal Varices

NCT00481416
View directory record Official record
Conditions
Esophageal Varices
Interventions
PillCam Eso
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Plymouth, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 31, 2026, 7:52 AM EDT
Not listed Phase 2 Interventional

Selective Dose Escalation for Esophageal Cancer

NCT00139633
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, 5FU, Taxol and radiation
Drug
Lead sponsor
The Oregon Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 31, 2005 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Telehealth-Delivered Gut-Directed Hypnotherapy for Managing GI Health

NCT06890663
View directory record Official record
Conditions
Gastrointestinal Disease, Gastrointestinal Disorders, Nervous System
Interventions
Nonspecific Hypnotherapy for Relaxation, Gut-Directed Hypnotherapy (GDH), 3-month Follow-Up
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 7:52 AM EDT
Recruiting Not applicable Interventional

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

NCT07027826
View directory record Official record
Conditions
Dysphagia, Eosinophilic Esophagitis
Interventions
Esophageal string test
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002304
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Ketoconazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 7:52 AM EDT
Enrolling by invitation Not applicable Interventional

Injection Versus Suture Repair of Laryngeal Clefts

NCT07057258
View directory record Official record
Conditions
Laryngeal Cleft, Dysphagia
Interventions
Endoscopic suture repair, Injection laryngoplasty
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Months to 10 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

NCT02081404
View directory record Official record
Conditions
Non-erosive Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 31, 2026, 7:52 AM EDT